Capricor director sells 115,000 shares after option exercise

CAPRICOR THERAPEUTICS director Karimah Es Sabar exercised stock options and sold the resulting shares in two days of trading.

Rhea-AI Filing Summary

CAPRICOR THERAPEUTICS director Karimah Es Sabar exercised stock options and sold the resulting shares in two days of trading. On March 31, 2026 and April 1, 2026, she exercised options to acquire a total of 115,000 shares of common stock at an exercise price of $4.86 per share and then sold all 115,000 shares in open-market transactions at weighted average prices of $30.1680 and $31.0268, respectively. Following these transactions, no shares from these exercised options remained held, and the sales were carried out under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025.

Insider Trade Summary 10b5-1

Exercise and Sale: 115,000 shares ($2.96M approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Sabar Karimah Es

Role Director

Sold 115,000 shs ($3.52M)

Approx. gross sale proceeds $3.52M

Approx. exercise cost $559K

Approx. pre-tax spread $2.96M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	53,735	$0.00	$0.00
Exercise	Common Stock	53,735	$4.86	$261K
Sale	Common Stock	53,735	$31.0268	$1.67M
Exercise	Stock Option (Right to Buy)	61,265	$0.00	$0.00
Exercise	Common Stock	61,265	$4.86	$298K
Sale	Common Stock	61,265	$30.168	$1.85M

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 0 shares (Direct)

Footnotes (4)

1. F1. Shares were sold pursuant to a 10b5-1 trading plan adopted in December 2025 by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
2. F2. The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.46, inclusive.
3. F3. The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $30.28 to $31.39, inclusive.
4. F4. Shares vested 25% on August 1, 2022 with the remainder vesting 1/36 per month commencing September 1, 2022.

Key Figures

Shares sold: 115,000 shares Options exercised: 115,000 shares Exercise price: $4.86 per share +3 more

6 metrics

Shares sold 115,000 shares Total CAPR common shares sold on March 31 and April 1, 2026

Options exercised 115,000 shares Total underlying shares from stock options exercised at $4.86

Exercise price <money>$4.86</money> per share Stock option exercise price for CAPR common stock

Sale price March 31 <money>$30.1680</money> per share Weighted average sale price for 61,265 shares on March 31, 2026

Sale price April 1 <money>$31.0268</money> per share Weighted average sale price for 53,735 shares on April 1, 2026

Net share change -115,000 shares Net buy/sell shares across reported transactions (net-sell)

Key Terms

Rule 10b5-1, weighted average price, Stock Option (Right to Buy), Exercise or conversion of derivative security, +1 more

5 terms

Rule 10b5-1 regulatory

"Shares were sold pursuant to a 10b5-1 trading plan adopted in December 2025"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

weighted average price financial

"The price reported on Column 4 is the weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

Exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

vesting financial

"Shares vested 25% on August 1, 2022 with the remainder vesting 1/36 per month"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did CAPR director Karimah Es Sabar report?

Karimah Es Sabar reported exercising stock options for 115,000 CAPR shares at $4.86 per share, then selling all 115,000 shares in open-market trades around $30–31 on March 31 and April 1, 2026, according to the Form 4.

At what prices were the CAPR shares sold in this Form 4 filing?

The CAPR shares were sold at weighted average prices of $30.1680 on March 31, 2026 and $31.0268 on April 1, 2026, with individual trades ranging from $30.00 to $31.39, as detailed in the Form 4 footnotes.

How many CAPRICOR THERAPEUTICS shares did the director sell overall?

The director sold a total of 115,000 CAPRICOR THERAPEUTICS common shares. This came from two same-day exercise-and-sell sequences: 61,265 shares on March 31, 2026 and 53,735 shares on April 1, 2026, matching the number of options exercised each day.

Were the CAPR insider sales made under a Rule 10b5-1 trading plan?

Yes. The Form 4 footnotes state the CAPR share sales were executed under a Rule 10b5-1 trading plan adopted in December 2025, indicating the transactions were pre-scheduled rather than decided at the time of sale.

What happened to the director’s stock options in this CAPR Form 4?

The director exercised stock options covering 61,265 shares and 53,735 shares of CAPR common stock at $4.86 per share. After these exercises, the reported option positions for these specific grants showed zero remaining shares following the transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 08:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sabar Karimah Es

(Last) (First) (Middle)

C/O CAPRICOR THERAPEUTICS, INC.

10865 ROAD TO THE CURE, SUITE 150

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CAPRICOR THERAPEUTICS, INC. [ CAPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		M		61,265	A	$4.86	61,265	D
Common Stock	03/31/2026		S(1)		61,265	D	$30.168(2)	0	D
Common Stock	04/01/2026		M		53,735	A	$4.86	53,735	D
Common Stock	04/01/2026		S(1)		53,735	D	$31.0268(3)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.86	03/31/2026		M			61,265	(4)	07/23/2031	Common Stock	61,265	$0	53,735	D
Stock Option (Right to Buy)	$4.86	04/01/2026		M			53,735	(4)	07/23/2031	Common Stock	53,735	$0	0	D

Explanation of Responses:

1. Shares were sold pursuant to a 10b5-1 trading plan adopted in December 2025 by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

2. The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.46, inclusive.

3. The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $30.28 to $31.39, inclusive.

4. Shares vested 25% on August 1, 2022 with the remainder vesting 1/36 per month commencing September 1, 2022.

	/s/ Linda Marban, Attorney-in-Fact	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)